news
FDA approves Keytruda for patients with high-risk, non-muscle invasive bladder cancer
Keytruda is the first anti-PD-1 monoclonal antibody therapy approved for patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer.
List view / Grid view
Bladder cancer
Filter the results
article
Top 10 drugs by annual revenue in 2025
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
news
Experimental nano-chemo particle to treat bladder cancer
Researchers have developed a way to successfully deliver nano-sized, platinum-based chemotherapy drugs to treat a form of bladder cancer...
news
FDA approves Merck’s bladder cancer drug
24 May 2017 | By Niamh Marriott, Junior Editor
The FDA has approved two new indications for Merck’s Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, for bladder cancer...
news
AstraZeneca’s bladder cancer treatment receives FDA approval
3 May 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca’s Imfinzi (durvalumab) to treat metastatic urothelial carcinoma...
news
Merrimack initiates Phase 1 study of MM-310 in solid tumours
29 March 2017 | By Niamh Marriott, Junior Editor
Merrimack Pharmaceuticals have enrolled its first patient in a Phase 1 study of MM-310 in solid tumours.
news
Global urological cancers market to double by 2022, says GBI Research
30 June 2016 | By Victoria White, Digital Content Producer
The urological cancers market will increase from $17.9 billion in 2015 to $35.9 billion by 2022, according to business intelligence provider GBI Research...
news
Tecentriq to dominate the bladder cancer market, says GlobalData
14 June 2016 | By Victoria White, Digital Content Producer
The launch of Roche’s Tecentriq will usher in a dramatic change in the treatment paradigm of bladder cancer, according to an analyst with GlobalData...
news
FDA grants priority review to Roche’s atezolizumab in urothelial carcinoma
15 March 2016 | By Victoria White
The priority review is based on results of the IMvigor 210 study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic urothelial carcinoma, regardless of PD-L1 expression.
news
Bladder cancer treatment market set to boom, says GlobalData
14 January 2016 | By Victoria White
The company states that the growth will be primarily down to the introduction of Telesta Therapeutics MCNA and Roche’s atezolizumab in 2016 and Bristol-Myers Squibb’s Opdivoin 2017...
news
Roche presents updated results for atezolizumab in mUC
8 January 2016 | By Victoria White
Median overall survival from the updated study results was 11.4 months in people with higher levels of PD-L1 expression, and 7.9 months in the overall study population...
news
Personalised peptide vaccine increased bladder cancer survival in study
18 November 2015 | By Victoria White
The median overall survival for patients assigned personalised peptide vaccine and best-supportive care was almost twice as long as that for patients assigned best-supportive care...
news
Ramucirumab improves progression-free survival in bladder cancer trial
28 September 2015 | By Victoria White
Median progression-free survival was 5.4 months on the ramucirumab-docetaxel arm as compared to 2.8 months for patients treated with docetaxel alone...
news
Atezolizumab could spur bladder cancer treatment innovation
28 July 2015 | By Victoria White
Atezolizumab is poised to become a major bladder cancer therapy in the race for FDA approval, following its promising performance in recent Phase II trials...
news
Atezolizumab shrank tumours in people with a specific type of bladder cancer in Phase II study
13 July 2015 | By Victoria White
In the Phase II IMvigor 210 study, Roche’s atezolizumab shrank tumours in people with locally advanced or metastatic urothelial bladder cancer (UBC)...